Expert says launch of Relonova in the Russian market has given doctors new options for treating migraines

On October 26-27, 2023, the First Russian Neurological Congress, one of the largest federal events for the medical community, took place in Moscow. At the congress, a report was presented by Elena FILATOVA (Doctor of Medical Sciences), Professor of the Department of Nervous System Diseases of the Institute of Professional Education of the Sechenov First Moscow State Medical University, on “New options for migraine therapy”, in which the speaker shared information on effective relief of migraine attacks – the possibilities of NSAID therapy and the new triptan in the Russian market, Relonova^®.

According to Dr. Filatova, “A patient having a migraine attack may experience headaches of varying intensity, which, accordingly, require different approaches to their relief. Diclofenac potassium in soft gelatin capsules called Difendum^® may be the best choice for patients with mild to moderate headaches. For patients with severe headaches, or moderate headaches when NSAIDs for some reason are not enough, we now have the option of using a new triptan, rizatriptan released under the name Relonova^®.”  

Speaking about the advantages of Relonova^® in comparison with another triptan, the expert pointed out that 36.6% of patients note complete relief of pain in 2 hours after taking the drug, which is 32% higher than the results of using sumatriptan*. Besides that, Professor believes it important that Relonova^® is produced in Russia and does not depend on foreign supplies.

At the end of the day, the congress brought together leading experts in the treatment of neurological diseases from all over the country, who used this opportunity to discuss a wide range of issues in all the key areas of neurology. Each participant discovered a wealth of useful and relevant information to help them provide better care to their patients.

* - Source: Cameron C. et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis, Headache. 2015 Jul-Aug;55 Suppl 4:221-35.